Speaker Profile
Ph.D., CEO, Therna Biosciences
Biography
Dr. Azimi is the co-founder and CEO of Therna Biosciences, a company that is leveraging its proprietary AI-models for RNA design to develop transformative RNA medicines for a variety of diseases. Prior to Therna Biosciences, she was the founder and CEO of Bioniz Therapeutics and Dermaheal, two biotech companies focused on immunological diseases. Dr. Azimi started her journey at the NIH as a post-doctoral fellow in immunology. She is interested in the intersection of science, strategy, and execution, building biotech companies from the ground up and helping teams translate innovation into outcomes.
Talk
RNA Design by Intelligent Design.
Using a biology-guided, AI-powered platform, Therna is pioneering programmable RNA therapeutics. Therna’s technology is engineered to enhance translation, durability, and precise tissue targeting, which unlocks new levels of safety and efficacy in RNA medicines.
AI for Emerging Therapeutics Showcase:
Therna Biosciences
AI/ML Powered RNA Medicines Therapeutics Company.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 AI for Emerging Therapeutics Showcase will provide a 15-30 minute time slot for selected companies to explore the transformative role of artificial intelligence in accelerating the discovery, development, and optimization of novel therapeutic modalities. From predictive algorithms for drug efficacy to real-time analysis in clinical trials, AI is revolutionizing the way we approach emerging therapies, including RNA-based treatments, gene editing, and personalized medicine. Industry leaders and experts will discuss AI-driven advancements, collaborative frameworks, and the challenges of integrating cutting-edge technologies into therapeutic innovation. Join us for an in-depth look at how AI is shaping the future of breakthrough therapeutics.
